Rallybio Corporation (RLYB)Healthcare | Biotechnology | New Haven, United States | NasdaqCM
16.81 USD
+0.05
(0.298%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 16.81 |
Hot Take ↕ | Aug. 22, 2026, 5:57 a.m. EDT
The immediate outlook is driven entirely by the announced merger with Avenzo Therapeutics, which has injected significant volatility and potential upside into the near term. The stock recently hit a two-year high following the deal announcement, and the presence of a substantial termination fee ($50M) suggests a high floor for shareholders if the deal fails, creating a compelling short-term catalyst for a momentum play. However, looking beyond the merger hype reveals a business in severe distress; the company has suffered four consecutive years of double-digit declines, with the share price collapsing nearly 95% over the last four years. This multi-year structural deterioration indicates that the market views the core biotechnology operations as failing to generate sustainable value without the merger. Furthermore, the company is burning cash rapidly, reporting negative free cash flow and negative operating margins, while offering no dividend support. While the merger provides a temporary lifeline and a speculative entry point, the underlying fundamentals are objectively broken, making this a high-risk situation where the long-term thesis is currently non-existent. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.030356 |
| MSTL | 0.034268 |
| AutoETS | 0.038074 |
| AutoARIMA | 0.038075 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 11.87 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.173 |
| Excess Kurtosis | -1.31 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.114 |
| Market Cap | 89,269,488 |
| Trailing P/E | 2.10 |
| Forward P/E | -3.11 |
| Beta | -0.86 |
| Profit Margins | 7051.24% |
| Website | https://www.rallybio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 2.7544804 |
| Address1 | 234 Church Street |
| All Time High | 206.24 |
| All Time Low | 1.76 |
| Ask | 21.6 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 10,400 |
| Average Daily Volume3 Month | 44,287 |
| Average Volume | 44,287 |
| Average Volume10Days | 10,400 |
| Beta | -0.857 |
| Bid | 11.89 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 9.504 |
| City | New Haven |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.81 |
| Current Ratio | 27.265 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 17.12 |
| Day Low | 16.51 |
| Display Name | Rallybio |
| Earnings Timestamp End | 1,754,569,800 |
| Earnings Timestamp Start | 1,754,569,800 |
| Ebitda | -25,380,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.141 |
| Enterprise To Revenue | -5.541 |
| Enterprise Value | -3,579,511 |
| Eps Current Year | -5.52 |
| Eps Forward | -5.4 |
| Eps Trailing Twelve Months | 7.99 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 16.2565 |
| Fifty Day Average Change | 0.5534992 |
| Fifty Day Average Change Percent | 0.03404787 |
| Fifty Two Week Change Percent | 275.44803 |
| Fifty Two Week High | 17.574 |
| Fifty Two Week High Change | -0.76399994 |
| Fifty Two Week High Change Percent | -0.04347331 |
| Fifty Two Week Low | 3.67 |
| Fifty Two Week Low Change | 13.139999 |
| Fifty Two Week Low Change Percent | 3.5803812 |
| Fifty Two Week Range | 3.67 - 17.574 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,565,400,000 |
| Float Shares | 2,177,517 |
| Forward Eps | -5.4 |
| Forward P E | -3.1129627 |
| Free Cashflow | -14,290,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 7 |
| Fullday Change | 0.0499992 |
| Fullday Change Percent | 0.298325 |
| Fullday Price | 16.81 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -16,542,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.042069998 |
| Held Percent Institutions | 2.29872 |
| Implied Shares Outstanding | 5,310,499 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-29 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,770,336,000 |
| Last Split Factor | 1:8 |
| Long Business Summary | Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut. |
| Long Name | Rallybio Corporation |
| Market | us_market |
| Market Cap | 89,269,488 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1673028342 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 45,551,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 89,003,963 |
| Open | 16.51 |
| Operating Cashflow | 26,712,000 |
| Operating Margins | -39.35449 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 203 859 3820 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 16.81 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 16.76 |
| Price Eps Current Year | -3.0452898 |
| Price Hint | 2 |
| Price To Book | 1.768729 |
| Price To Sales Trailing12 Months | 138.18806 |
| Profit Margins | 70.512375 |
| Quick Ratio | 26.03 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0499992 |
| Regular Market Change Percent | 0.298325 |
| Regular Market Day High | 17.12 |
| Regular Market Day Low | 16.51 |
| Regular Market Day Range | 16.51 - 17.12 |
| Regular Market Open | 16.51 |
| Regular Market Previous Close | 16.76 |
| Regular Market Price | 16.81 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 5,760 |
| Return On Assets | -0.21319 |
| Return On Equity | 0.6486 |
| Revenue Per Share | 0.114 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 5,310,499 |
| Shares Percent Shares Out | 0.010299999 |
| Shares Short | 54,564 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 170,156 |
| Short Name | Rallybio Corporation |
| Short Percent Of Float | 0.0124 |
| Short Ratio | 1.56 |
| Source Interval | 15 |
| State | CT |
| Symbol | RLYB |
| Total Cash | 92,849,000 |
| Total Cash Per Share | 17.484 |
| Total Debt | 0 |
| Total Revenue | 646,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 7.99 |
| Trailing P E | 2.10388 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.413025 |
| Two Hundred Day Average Change | 6.3969746 |
| Two Hundred Day Average Change Percent | 0.61432433 |
| Type Disp | Equity |
| Volume | 5,760 |
| Website | https://www.rallybio.com |
| Zip | 6,510 |